What is the Knowledge Hub?
Explore the VoICE Knowledge Hub—a searchable database featuring the latest peer-reviewed research on immunization benefits, especially in low- and middle-income countries. Browse the Knowledge Hub using a variety of different filters to find vaccine evidence based on country, region, topic, or disease. Click on a tag to find more evidence on a specific area, such as the return on investment of vaccines or impacts of infectious disease outbreaks.
Search
Diseases & Vaccines
Country
WHO Regions
Topics
Immunization Terms
Vaccinating pregnant women with dTpa vaccine greatly reduces severe pertussis in infants
A case-control study in the state of New South Wales, Australia estimated that vaccination of pregnant women with the dTpa vaccine at 28-32 weeks of pregnancy was highly effective in preventing severe pertussis in infants less than 6 months of age — with a vaccine efficacy rate of 94% against pertussis hospitalizations — and 69% effective in preventing the disease of any severity in infants less than 3 months old.
Note: The formulation used in this study is abbreviated dTpa.
Saul N, Wang K, Bag S et al.. 2018. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: the NSW Public Health Network case-control study. Vaccine. 36(14).
Adding dTpa vaccination for pregnant women in Australia would prevent thousands of pertussis hospitalizations each year
A study in Australia estimated that adding dTpa vaccination for pregnant women to the current pertussis immunization program for children would prevent an additional 8,800 symptomatic pertussis cases (mostly unreported) and 146 hospitalizations each year in all ages, including infants and their mothers, as well as one death every 22 months. The study found maternal pertussis vaccination to be cost-effective.
Note: The formulation used in this study is abbreviated dTpa.
Saul N, Wang K, Bag S et al.. 2018. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: the NSW Public Health Network case-control study. Vaccine. 36(14).
Immunization against rotavirus has led to significant decreases in hospital admissions and gastroenteritis cases
Several countries have seen a significant decrease in the number of rotavirus-related hospital admissions in rotavirus unvaccinated children ages 2-5 years who were not age eligible to receive the vaccine post introduction. The US had a 41-92% decrease, Australia had a 30-70% decrease, Belgium had a 20-64% decrease, Austria had a 35% reduction and El Salvador had a 41-81% decrease. In addition, there was a reduction in hospitalizations due to gastroenteritis of any cause by 17-51% in the US and 40% in Australia.
Patel, M.M., Glass, R., Desai, R., et al.. 2012. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?. Lancet Infectious Diseases. 12(7).
Funding a national pneumonia vaccine program increased vaccine coverage among the elderly
A publicly funded 23vPPV (23 valent pneumococcal polysaccharide vaccine) program in Victoria, Australia not only dramatically increased vaccination coverage among the elderly in the public purchase program, but in other Australian states and territories that did not have a public program, the number of prescriptions issued for 23vPPV actually increased over the same period.
Andrews, R.M.. 2005. Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia. Vaccine. 23(21).